Non categorizzato Eli Lilly’s obesity drug nears approval in Japan, CEO confirms Ottobre 11, 2024 0 commenti Eli Lilly Chair and CEO David Ricks announced on Friday that the company’s popular obesity treatment, Zepbound, will be approved in Japan by mid-2025. Speaking with Nikkei Assia, Ricks confirmed that … About the author:
Get involved!
Comments